Appia Bio Shuts Down Cell Therapy Operations After Failed Partnership with Kite Pharma
核心洞察
Appia Bio (搜索), a cell therapy company founded in 2020, has officially ceased operations after four years in business, citing lack of funding to advance clinical testing.
The biotech had developed CAR-engineered natural killer T cell therapies and secured a $875 million collaboration with Kite Pharma (搜索) in 2021, which ended in 2024.
Appia's closure adds to a growing list of biotech shutdowns in 2025, including Abata Therapeutics (搜索), NextRNA Therapeutics (搜索), and iTeos Therapeutics, reflecting broader industry funding challenges.
Appia Bio (搜索), a biotechnology company specializing in off-the-shelf cell therapies, has officially shut down operations after four years in business, becoming the latest casualty in a wave of biotech closures that have swept the industry throughout 2025.
CEO JeenJoo Kang announced the closure in a LinkedIn post on Monday, stating, "I am saddened to share that we decided to wind down Appia Bio (搜索). Without further funding available to test in patients, heartbreakingly, we had reached the end of our road."
Company Background and Technology Platform
Founded in 2020, Appia emerged from stealth mode in May 2021 with $52 million in Series A funding. The company was established by a team of industry veterans, including alumni from Kite Pharma (搜索), with Nobel laureate David Baltimore serving as chairman of the board alongside academic experts in genetics and chemical engineering.
The biotech's core technology centered on a drug development engine that generates CAR-engineered natural killer T cells (搜索). These engineered cells could be frozen and stored until needed for patient treatment, offering the potential for off-the-shelf cell therapy solutions across various oncology (搜索) indications.
Kite Pharma Partnership and Its End
Appia's technology platform attracted significant industry attention, leading to a major collaboration with Kite Pharma (搜索) in August 2021. The partnership focused on advancing stem cell-derived cell therapies for hematologic cancers (搜索) and covered two therapeutic candidates. The collaboration carried a potential value of $875 million, including upfront consideration and milestone payments.
However, the partnership with Kite ended in 2024, marking a significant setback for the company's development trajectory and financial stability.
Clinical Development Progress
Despite the funding challenges, Appia made substantial progress in its drug development efforts. According to Kang, the company "got to the cusp of filing our IND [investigational new drug] for clinical testing" before ultimately running out of resources to continue operations.
Industry-Wide Funding Crisis
Appia's closure reflects broader challenges facing the biotechnology sector, with multiple companies shuttering operations throughout 2025 due to difficult fundraising conditions. The company joins a growing list of biotech casualties this year, including several notable closures just in recent months.
Abata Therapeutics (搜索), which had been developing regulatory T cell therapies (搜索) for autoimmune and inflammatory diseases (搜索), decided to close operations in August due to "the current fundraising environment," according to a spokesperson from Third Rock Ventures (搜索). The company had launched in 2021 with Third Rock's support.
NextRNA Therapeutics (搜索) also announced its shutdown earlier in August, with CEO Dominique Verhelle revealing the decision to cease operations. Additional companies that have exited the market include Oncternal Therapeutics in July, National Resilience in June, and Vor Bio in May.
iTeos Therapeutics announced in May that it would cease operations and sell off its remaining assets and intellectual properties following a strategic review. The closure came after iTeos lost its partnership with GSK, which walked away from a 2021 collaboration focused on an anti-TIGIT therapy (搜索) for cancer (搜索).
The series of biotech shutdowns highlights the challenging funding environment that has persisted throughout 2025, forcing companies to make difficult decisions about their future operations despite promising scientific platforms and therapeutic approaches.